Skip to main content

Matilde Lleonart Pajarin

Institutions of which they are part

Head of group
Biomedical Research in Cancer Stem Cells
Vall Hebron Institut de Recerca

Matilde Lleonart Pajarin

Institutions of which they are part

Head of group
Biomedical Research in Cancer Stem Cells
Vall Hebron Institut de Recerca

Research lines

Identificación y caracterización de poblaciones de CSCs ("cancer stem cells") en tumores

A partir de diversos tipos de cánceres que incluyen desde mama, pulmón, cabeza y cuello, en particular los más letales (faringe y laringe), aislamos poblaciones de CSCs para determinar su caracterización completa e implicación en la clínica.

IP: Matilde Lleonart Pajarin

Detección precoz de cáncer mamario antes de que éste se manifieste

A partir de datos preliminares de arrays, hemos caracterizado algunos microRNAs/mRNAs relevantes en tumores. Actualmente los estamos analizando a nivel de pacientes con cáncer en sangre como posible método predictivo antes de la aparición del tumor.

IP: Matilde Lleonart Pajarin

Estudio de proteínas de unión a RNA como nuevos factores pronóstico y diagnóstico en cáncer

En nuestro laboratorio hemos efectuado diversos “screenings” genéticos para detectar nuevos genes implicados en proliferación celular in vitro que además poséan un papel relevante en cáncer humano. De entre ellos descubrimos la proteínas CIRP, la cual hemos descrito como proteína oncogénica. Actualmente estamos valorando la función de CIRP en diversos tipos tumorales en correlación con la evolución clínica de los pacientes.

IP: Matilde Lleonart Pajarin

Study of new genes involved in proliferation

Searching for new proliferative genes/tumor suppressor genes is being performed at our laboratory by carring out genetic screens. By the use of retroviral vectors as carriers of a cDNA libraries (formed by mRNA from murine embryonic stem cells), primary cells are infected and screening for those clones able to bypass senescence are selected for further characterization. The marked morphological heterogeneity observed in several tumorigenic process, support the hypothesis that several cancers have their origin in a stem cell. It is believed that genes expressed by embryonic stem cells, may play an important role in the tumorigenic mechanism.This project unravels the effect of immortal genes existing in embryonic stem cells, when are forced to be expressed in primary and thereby mortal cells. These immortal genes are future candidate markers in tumors with potential prognosis value. The novel genes discovered, are being analyzed in the biopsies from patients with different kinds of tumors collected at the Pathology Department of the Vall d´Hebrón Hospital.

IP: Matilde Lleonart Pajarin

Projects

Beca VHIR PhD

IP: Matilde Lleonart Pajarin
Collaborators: Sira Rodrigo Bosch, Laia Perez Lasarte, Marina Bataller Fernández
Funding agency: Fundació Institut de Recerca HUVH
Funding: 69188.74
Reference: VPHD/MARINA_B
Duration: 01/04/2023 - 31/03/2026

Therapeutical approaches against chemoresistant cancers

IP: Matilde Lleonart Pajarin
Collaborators: Yoelsis Garcia Mayea, Fco. Xavier De la Cruz Montserrat, Juan Lorente Guerrero, Cristina Mir Perez, Natalia Padilla Sirera, Marina Bataller Fernández, Almudena Sanchez Garcia, Selen Ozkan
Funding agency: AGAUR no fer servir-correcte 4301-37
Funding: 0.01
Reference: 2021 SGR 01205
Duration: 01/01/2022 - 31/12/2024

Ayudas Margarita Salas

IP: Matilde Lleonart Pajarin
Collaborators: Yoelsis Garcia Mayea, Judit Álvarez González
Funding agency: Ministerio de Universidades
Funding: 0.01
Reference: MIU/M_SALAS/2021/GARCIA_UB
Duration: 01/04/2022 - 31/03/2022

Novel terapéutic approaches against COVID-19

IP: Matilde Lleonart Pajarin
Collaborators: Cristina Mir Perez, Marina Bataller Fernández, Almudena Sanchez Garcia, Emily Marisol Toscano Guerra
Funding agency: Fundació La Marató de TV3
Funding: 161875
Reference: 202116
Duration: 23/09/2021 - 22/09/2024

Related news

Vall d’Hebron ha celebrat avui la Jornada del Dia Mundial contra el Càncer, una malaltia cada cop més freqüent que patiran al llarg de la vida un de cada dos homes i una de cada tres dones del nostre entorn.

The work has compared sensitive and resistant cells to cisplatin treatment to understand the mechanisms involved in resistance and to find new biomarkers and therapies.

On World Cancer Research Day, we highlight the impact of VHIR projects in the field of oncology.

Related professionals

Eva Polverino

Eva Polverino

Main researcher
Pneumology
Read more
Estefania Montiel

Estefania Montiel

Main researcher
Stroke research
Read more
Danila Guagnozzi

Danila Guagnozzi

Main researcher
Physiology and Pathophysiology of the Digestive Tract
Read more
Baye Elimane Thiaw

Baye Elimane Thiaw

Maintenance staff and general services
Infectious Diseases
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.